Pfizer Launches Global Commercial Analytics Centre in India

Pfizer launches 'Analytics Gateway' in India, its first dedicated global commercial analytics centre

Pfizer Inc has launched the company's first ever dedicated commercial analytics centre in India called, the 'Analytics Gateway'. The centre located in Mumbai represents a milestone in Pfizer's international commercial strategy and is positioned to be a global capability centre for all of Pfizer's international (outside of the US) markets to bring analytics, and insight breakthroughs that will benefit patients, a note from the company said. The centre comprises an experienced pool of data and analytics experts, it added. 'Recognition of India's talent' The centre is expected to accelerate data science and AI solutions to meet Pfizer's ambitions in modernising marketing and creating an agile sales force. It will also drive continuous commercial effectiveness, enabling Pfizer to bring more of its medicines to more patients in India and around the world. Meenakshi Nevatia, Country President, Pfizer India, said, the centre is an important recognition of the skilled talent in data science and analytics that India can offer to the globe. SHARE Copy linkEmailFacebookTwitterTelegramLinkedInWhatsAppRedditPublished on September 18, 2024

Pfizer sets up global capability centre in India - Times of India

NEW DELHI: Pfizer Inc launched the company's first-ever dedicated commercial analytics centre in India, which is also the company's first global capability centre for international markets. The 'Analytics Gateway' located in Mumbai is positioned to be a global capability centre (GCC) serving all of Pfizer's international (ex-US) markets to bring analytics, and insight breakthroughs that will benefit patients, says a company statement. The centre represents a significant milestone in Pfizer's international commercial strategy and will play a pivotal role in driving the company's growth across 140 international markets, utilizing cutting-edge data analytics, AI, and insights, it adds. This comes even as several MNCs and pharma companies are shifting their India strategy from marketing and distribution, to setting up GCCs to support their international operations. India, dubbed as the GCC capital of the world, is reportedly expected to cross over $100 billion in GCC export revenue by 2029-30 financial year, up from $64.6 billion in 2023-24. The centre that is set up in Mumbai, is expected to accelerate data science and AI solutions to meet Pfizer's ambitions in modernizing marketing and creating an agile sales force. It will also drive continuous commercial effectiveness, enabling Pfizer to bring more of its medicines to more patients in India and around the world. Meenakshi Nevatia, country president, Pfizer India, said, "The actionable insights generated by the Analytics Gateway will power up our global commercial engine as we modernize healthcare to meet the evolving needs of patients in India and worldwide and deliver strong patient outcomes." A business journalist with around two decades of experience tracking key consumer-focussed sectors like consumer durables, retail, consumer goods, aviation, automobiles and advertising, as well as economic ministries of the Union government. Now, writes primarily on pharmaceuticals and healthcare, and on issues of consumer interest. Besides also looks at trends that are shaping consumer behaviour and the broad consumer landscape. \nYou can follow Rupali on Twitter@Rupalijee.